I-FIGS Feasibility Study
- Conditions
- Liver Metastasis Colon CancerLiver CancerHepatocellular Carcinoma
- Registration Number
- NCT05616039
- Lead Sponsor
- University Hospital Plymouth NHS Trust
- Brief Summary
Background:
Removal of part of the liver (resection) is performed as a treatment for some cancers in the liver. To achieve the best possible outcomes, it is important that the cancer is removed completely (R0 resection) (1). Up to 30-50% patients develop recurrence within 2 years of surgery which could be due to incomplete removal of the cancer (2). Various techniques are used by the surgeons to identify the cancer tissue from the normal liver during the surgery so that it can be removed completely. These include examining with the naked eye, having a feel of the tumour, and performing an ultrasound scan. Even with these techniques it is difficult to identify the exact extent of the cancer. Also, the interpretation of the ultrasound scan can be subjective (3). A robust, objective, real-time navigation technique is required which can differentiate cancer from normal tissue.
Indocyanine green (ICG) is a dye which when given through the veins, is taken up and retained by cancer cells in the liver and they appear as fluorescent areas as compared to normal liver which appears dark. This principle can be used to identify the cancerous tissue accurately during the surgery and remove it completely (Indocyanine green Fluorescence Image-Guided Surgery: I-FIGS). It can also potentially detect additional tumours which were not identified before the surgery or during the surgery with standard techniques (4,5). However, there is a lack of good quality evidence on the usefulness of I-FIGS in liver surgery, so this needs to be tested in a large group of patients having liver surgery before any recommendations can be made.
Research Aim:
This initial study aims to assess whether a larger trial evaluating the role of I-FIGS in complete removal of the cancer tissue is feasible. Investigators will assess if patients are willing to take part in the study and whether they can gather relevant clinical outcome data from them all. Investigators will also gather patients' views about this novel technique and participating in the study.
Design and methods:
This study will involve 40 patients having planned liver surgery for liver tumour/s recruited from University Hospitals, Plymouth. Patients will be randomly allocated to have I-FIGS plus standard surgery or standard liver surgery alone. Patients in the I-FIGS group will have ICG injection 2-4 hrs prior to surgery (0.03-0.05mg/kg dose) on the day of surgery. The surgical planning will be carried out as per the standard approach using the naked eye and intra-operative ultrasound examination. Once this is all recorded, ICG cameras will be switched on, and the additional findings and change to surgical plan will be noted. Focus groups will explore participants experiences of being in the study. This will inform the design of the future larger trial.
Patient public involvement:
Investigators have involved patients who have had or are having liver surgery in the development of the study. Their views on the technique, trial procedures and outcome measures have been incorporated. They will continue to be involved and advise on the study.
Dissemination:
Results will be available via research journals and conferences.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 42
• All adult patients (>16 years) requiring elective open/laparoscopic liver resection/s for liver metastases, primary hepatocellular and peripheral cholangiocarcinoma will be included in the study.
- Patients allergic to iodine/contrast or shellfish
- Patients unable to consent to the study
- Patients with suspected liver adenomas and biliary cystadenomas
- Patients with suspected hilar cholangiocarcinoma
- Patients requiring emergency liver surgery
- Pregnant patients
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Feasibility outcomes 10 weeks (from the day of recruitment till the histopathology report is available) * screening and recruitment rate
* retention rate
* adherence rates to study methods and procedures (consent, randomisation, intervention, data collection)Clinical outcomes- Microscopic positive resection margin rate From the day of surgery till the histopathology report is available (approximately 6 weeks) Number of patients with microscopic positive resection margins as compared to total number of patients, measured as percentage.
Microscopic positive resection margin is defined as presence of tumour cells \< 1 mm from the resection margin.
- Secondary Outcome Measures
Name Time Method Duration of surgery On the day of surgery This will be measured in minutes on the day of surgery. This will include the time from the time incision is taken (knife to skin) till the patient is extubated. A median value and range will be calculated for both the groups.
Post-operative length of stay From the day of surgery till the day of discharge (approximately 10 days) This will be measured in number of days for each patient. A median value and range will be calculated for both the groups.
Complications From the day of recruitment till the day of discharge (approximately 4 weeks) If case of any complications, these will be graded as per the Clavien-Dindo grading system.
The unit of measure will be the Clavien-Dindo grade.Number of additional tumours detected On the day of surgery Number of additional tumours detected by I-FIGS compared to Intra-operative ultrasound scan (IOUS) will be noted for each patient. A median value and range will be calculated for both the groups.
Trial Locations
- Locations (1)
University Hospitals Plymouth NHS Trust
🇬🇧Plymouth, United Kingdom
University Hospitals Plymouth NHS Trust🇬🇧Plymouth, United Kingdom